Literature DB >> 2979226

Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole.

S Lanzon-Miller1, R E Pounder, M R Hamilton, S Ball, N A Chronos, F Raymond, M Olausson, C Cederberg.   

Abstract

Simultaneous 24-hour intragastric acidity and plasma gastrin concentrations were measured in 12 duodenal ulcer patients before and on the twenty-eighth day of treatment with either ranitidine 150 mg b.d. or omeprazole 20 mg o.m. Median integrated 24-hour intragastric acidity was decreased significantly from 1148 to 490 and 36 mmol.hour litre-1 during treatment with ranitidine and omeprazole, respectively, whilst median intragastric 24-hour plasma gastrin was raised significantly from 328 to 799 and 1519 pmol.hour litre-1 respectively. When the results of all 48 experiments were considered together, there was a significant inverse correlation between the 24-hour integrated values for intragastric acidity and plasma gastrin concentration. Both drugs caused a significant elevation of plasma gastrin throughout the 24 hours, although ranitidine had no effect on intragastric acidity from 1900 to 2200 hours. When compared with similar profiles of acidity and gastrin in pernicious-anaemia patients, the modest elevations of plasma gastrin observed in this study suggest that neither drug will be associated with clinically relevant enterochromaffin-like cell proliferation in duodenal ulcer patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2979226     DOI: 10.1111/j.1365-2036.1987.tb00623.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  49 in total

1.  Does fasting serum gastrin predict gastric acid suppression in patients on proton-pump inhibitors?

Authors:  E S Bonapace; R S Fisher; H P Parkman
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

2.  Acid suppression.

Authors: 
Journal:  BMJ       Date:  1990-12-08

3.  Omeprazole.

Authors:  M J Langman
Journal:  BMJ       Date:  1991-08-31

4.  H2 antagonist and omeprazole nonresponders.

Authors:  V Savarino; G S Mela; S Vigneri; G Celle
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

5.  Chronic omeprazole treatment increases duodenal susceptibility to ethanol injury in rats.

Authors:  R A Erickson; S Bezabah; G Jonas; E Lifrak; A S Tarnawski
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

6.  Omeprazole: gastrin and gastric data.

Authors:  K G Wormsley
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

7.  Weekend treatment with 20 and 40 mg omeprazole: effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens.

Authors:  L C Baak; J B Jansen; I Biemond; C B Lamers
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

8.  Omeprazole: gastrin and gastric data (August 1991)

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-10       Impact factor: 3.199

Review 9.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

10.  Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man.

Authors:  J L Meijer; J B Jansen; L F Crobach; I Biemond; C B Lamers
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.